Cargando…
LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis
BACKGROUND: Ovarian cancer (OC) is a high-mortality gynecological cancer that is typically treated with cisplatin, although such treatment often results in chemoresistance. Ovarian cancer resistance is usually related to cell stemness. Herein, we explored the function of lncRNA WDFY3-AS2 in OC cell...
Autores principales: | Wu, Yue, Wang, Ting, Xia, Lin, Zhang, Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164817/ https://www.ncbi.nlm.nih.gov/pubmed/34051810 http://dx.doi.org/10.1186/s12935-021-01993-x |
Ejemplares similares
-
Correction to: LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis
por: Wu, Yue, et al.
Publicado: (2023) -
LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis
por: Zhao, Peng, et al.
Publicado: (2021) -
LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis
por: Liu, Yanjie, et al.
Publicado: (2020) -
LncRNA MIR4435-2HG triggers ovarian cancer progression by regulating miR-128-3p/CKD14 axis
por: Zhu, Lijuan, et al.
Publicado: (2020) -
LncRNA TRPM2-AS promotes ovarian cancer progression and cisplatin resistance by sponging miR-138-5p to release SDC3 mRNA
por: Ding, Yi, et al.
Publicado: (2021)